10.32 -0.07 (-0.66%)
After hours: 4:11PM EDT
|Bid||10.30 x 900|
|Ask||10.79 x 1300|
|Day's Range||10.03 - 10.50|
|52 Week Range||4.35 - 10.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Invitae (NVTA) delivered earnings and revenue surprises of 16.07% and 21.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Francisco-based company said it had a loss of 47 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
-- Raising annual revenue guidance amid strong quarter performance -- -- Q2 2018 gross profit of $16.9M up from $3.8M in Q2 2017 -- -- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Invitae Corp. (NYSE: NVTA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...
SAN FRANCISCO, July 24, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3497996. Invitae Corporation (NVTA) is a genetic testing and information company.
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on IQV sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following Medical Laboratories and Research stocks for review this morning: iKang Healthcare Group Inc. (NASDAQ: KANG), Invitae Corp. (NYSE: NVTA), IQVIA Holdings Inc. (NYSE: IQV), and Laboratory Corp. of America Holdings (NYSE: LH).
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced the launch of the Invitae Carrier Screen, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder. "By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be have the information they need to make appropriate health decisions when starting a family," said Robert Nussbaum, M.D., chief medical officer of Invitae.
SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and suggested that CNV testing should be universally used in clinical genetic testing. With few exceptions, these types of exonic CNVs are not typically detectable or reported from cytogenetic methods such as whole-genome chromosomal microarrays.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago. Invitae Corporation (NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices.
On a per-share basis, the San Francisco-based company said it had a loss of 66 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
-- Raising annual volume and revenue guidance -- -- Q1 2018 gross profit of $9.6M up from $1.0M in Q1 2017 -- -- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific -- ...
The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu
Today we've highlighted five stocks that are currently trading for under $10 per share. All of these stocks currently sport a Zacks Rank #2 (Buy) or better, and the selected companies are showing signs of outpacing the market in the current calendar year.
Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers
"Our partnership with Invitae is important to advancing our clinical study objectives across our entire RNA-based platform," said Doug Ingram, Sarepta's President and CEO. DMD is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500 – 5,000 males worldwide and is caused by a change or mutation in the gene that encodes instructions for dystrophin.